Drug Trial Radar · NCT03583164
Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
203
Actual
Start
Jun 6, 2018
Primary completion
Feb 10, 2023
Study completion Feb 10, 2023
Sponsor
- Lead sponsor
- F2G Biotech GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Jul 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate olorofim (F901318) for the treatment of invasive fungal infections in participants lacking suitable alternative treatment options.
Conditions
- Invasive Fungal Infections
Interventions
OlorofimDrug
30mg oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Data Review Committee (DRC) Adjudicated Overall Response at Day 42Time frame: Day 42 in the Main Phase of study treatment
Locations
82 sites in 17 countries. Site status is shown where the registry gives one.
Valley Fever Institute at Kern Medical Center
Bakersfield, California
UC Davis Medical Center
Sacramento, California
University of California San Diego Medical Center
San Diego, California
Emory University
Atlanta, Georgia
University of Chicago
Chicago, Illinois
Johns Hopkins Hospital
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Weill Cornell Medical College
New York, New York
Stony Brook University Medical Center
Stony Brook, New York
Duke University Health System
Durham, North Carolina
UPMC
Pittsburgh, Pennsylvania
University of Texas MD Anderson Cancer Center
Houston, Texas
The University of Texas Health Science Center at San Antonio
San Antonio, Texas
Westmead Hospital
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Peter MacCallum Centre-East Melbourne
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Institut Jules Bordet
Brussels, Belgium
Hôpital Erasme
Brussels, Belgium
UZ Leuven
Leuven, Waals-Brabant, Belgium
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
Curitiba, Brazil
Santa Casa de Misericórdia de Passos
Passos, Brazil
Hospital Felício Rocho
Belo Horizonte, Minas Gerais, Brazil
Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil
HC - UFPR - Hospital de Clínicas da Universidade Federal do Paraná
Curitiba, Paraná, Brazil
Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital da Universidade Federal de Santa Maria CEP/UFSM
Santa Maria, Rio Grande do Sul, Brazil
Oncology Center, Mansoura University
Al Mansurah, Egypt
Alexandria University Hospital
Alexandria, Egypt
Cairo University Hospitals
Cairo, Egypt
Ain Shams University Hospital
Cairo, Egypt
Air Force Specialized Hospital
Cairo, Egypt
National Cancer Institute
Cairo, Egypt
Nasser Institute
Cairo, Egypt
Hôpital Saint-Louis
Paris, France
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.